Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Raised by New York State Common Retirement Fund

Posted by Defense World Staff on Apr 18th, 2023

New York State Common Retirement Fund lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,953 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,615 shares during the quarter. New York State Common Retirement Fund owned about 0.17% of Jazz Pharmaceuticals worth $17,517,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. US Bancorp DE grew its holdings in Jazz Pharmaceuticals by 13.3% during the first quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 322 shares during the period. Private Advisor Group LLC acquired a new position in Jazz Pharmaceuticals during the first quarter worth about $547,000. Aviva PLC grew its holdings in Jazz Pharmaceuticals by 87.1% during the first quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock worth $6,228,000 after acquiring an additional 18,628 shares during the period. Allianz Asset Management GmbH grew its holdings in Jazz Pharmaceuticals by 118.2% during the first quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after acquiring an additional 6,571 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Jazz Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock worth $872,164,000 after acquiring an additional 57,949 shares during the period. 89.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Needham & Company LLC lowered their target price on Jazz Pharmaceuticals from $210.00 to $205.00 and set a “buy” rating on the stock in a report on Thursday, March 2nd. HC Wainwright reissued a “buy” rating and issued a $204.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, March 6th. The Goldman Sachs Group lifted their price target on Jazz Pharmaceuticals from $190.00 to $212.00 and gave the stock a “buy” rating in a research note on Friday, March 3rd. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 13th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $204.27.

Jazz Pharmaceuticals Trading Up 0.3 %

NASDAQ:JAZZ opened at $145.93 on Tuesday. The company has a debt-to-equity ratio of 1.85, a current ratio of 2.79 and a quick ratio of 2.03. Jazz Pharmaceuticals plc has a fifty-two week low of $125.36 and a fifty-two week high of $169.89. The stock’s 50-day moving average is $143.62 and its two-hundred day moving average is $147.28. The stock has a market cap of $9.24 billion, a PE ratio of -41.11, a price-to-earnings-growth ratio of 0.83 and a beta of 0.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last released its earnings results on Wednesday, March 1st. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter. Jazz Pharmaceuticals had a negative net margin of 6.12% and a positive return on equity of 24.04%. The business had revenue of $972.12 million for the quarter, compared to analysts’ expectations of $972.70 million. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 14.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $155.79, for a total transaction of $155,790.00. Following the transaction, the chief executive officer now owns 367,078 shares of the company’s stock, valued at approximately $57,187,081.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $155.79, for a total transaction of $155,790.00. Following the transaction, the chief executive officer now owns 367,078 shares of the company’s stock, valued at approximately $57,187,081.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,148 shares of Jazz Pharmaceuticals stock in a transaction dated Sunday, March 5th. The shares were sold at an average price of $140.76, for a total value of $161,592.48. Following the sale, the chief accounting officer now owns 7,309 shares of the company’s stock, valued at $1,028,814.84. The disclosure for this sale can be found here. Insiders have sold a total of 10,580 shares of company stock valued at $1,492,500 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.